Simvastatin and sildenafil combine to attenuate pulmonary hypertension

European Respiratory Journal

Volumn 34, Issue 4, 2009, Pages 948-957

  Zhao, L ^a   Sebkhi, A ^a   Ali, O ^a   Wojciak Stothard, B ^b   Mamanova, L ^a   Yang, Q ^a   Wharton, J ^a   Wilkins, M R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Animal models; Hypoxia; Pulmonary hypertension; RhoA; Sildenafil; Simvastatin

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; LUNG; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; MONOTHERAPY; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANOXIA; CYCLIC GMP; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIMVASTATIN; SULFONES;

EID: 70349649065     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00143508     Document Type: Article

References (39)

1. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006; 21: 385-392.
2. Ali O, Wharton J, Gibbs JS, et al. Emerging therapies for pulmonary arterial hypertension. Expert Opin Invest Drugs 2007; 16: 803-818. (Pubitemid 46882355)
3. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 22, 51: 1527-1538.
4. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63: Suppl. 2, ii1-ii41.
5. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
6. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005; 45: 89-118.
7. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334. (Pubitemid 43755328)
8. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007; 37: 681-691. (Pubitemid 47256168)
9. Carlin CM, Peacock AJ, Welsh DJ. Fluvastatin inhibits hypoxic proliferationand p38 MAPK activity in pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 2007; 37: 447-456.
10. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000; 275: 21722-21729. (Pubitemid 30481881)
11. Sauzeau V, Rolli-Derkinderen M, Marionneau C, et al. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003; 278: 9472-9480. (Pubitemid 36800439)
12. Guilluy C, Sauzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005; 146: 1010-1018. (Pubitemid 41722174)
13. Sauzeau V, Rolli-Derkinderen M, Lehoux S, et al. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 2003; 93: 630-637. (Pubitemid 37222159)
14. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H938-H945. (Pubitemid 37048146)
15. Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 401-414. (Pubitemid 44401411)
16. Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 2335-2342. (Pubitemid 41552651)
17. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166: 1403-1408. (Pubitemid 35292709)
18. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291: L668-L676. (Pubitemid 44498478)
19. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-1645. (Pubitemid 37187793)
20. Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1105-L1110. (Pubitemid 47084854)
21. Satoh K, Fukumoto Y, Nakano M, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009; 81: 226-234.
22. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005; 127: 1446-1452. (Pubitemid 46224314)
23. Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107: 3230-3235. (Pubitemid 36793096)
24. Zhao L, Mason NA, Strange JW, et al. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 2003; 107: 234-237. (Pubitemid 36135217)
25. Ren XD, Schwartz MA. Regulation of inositol lipid kinases by Rho and Rac. Curr Opin Genet Dev 1998; 8: 63-67.
26. McMurtry MS, Bonnet S, Michelakis ED, et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007; 293: L933-L940. (Pubitemid 47572241)
27. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291: L668-L676. (Pubitemid 44498478)
28. Stenmark KR, McMurtry IF. Vascular remodelling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 2005; 97: 95-98.
29. 2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1220-L1229.
30. Wojciak-Stothard B. New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling. Postgrad Med J 2008; 84: 348-353.
31. Oka M, Fagan KA, Jones PL, et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155: 444-454.
32. Mack CP, Somlyo AV, Hautmann M, et al. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001; 276: 341-347. (Pubitemid 32050325)
33. Yoneda A, Ushakov D, Multhaupt HA, et al. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and -II. Mol Biol Cell 2007; 18: 66-75. (Pubitemid 46066711)
34. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for Rho-kinase inhibitors. Tohoku J Exp Med 2007; 211: 309-320. (Pubitemid 46585544)
35. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 20, 94: 385-393. (Pubitemid 38240731)
36. Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004; 287: L656-L664. (Pubitemid 39249378)
37. Abe K, Tawara S, Oi K, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006; 48: 280-285. (Pubitemid 46066832)
38. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000; 87: 526-528.
39. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-1939. (Pubitemid 39331904)